LITS missed EPS expectations by 88.56%
Sep 13, 2025, 10:34 PM
0.00%
What does LITS do
MEI Pharma, based in San Diego, develops pharmaceutical compounds and employs 46 staff. Its drug pipeline includes Voruciclib, a CDK9 inhibitor in Phase 1 trials for AML, and ME-344, a mitochondrial inhibitor.
Lite Strategy (LITS) reported a negative EPS surprise in its most recent quarterly earnings. For the most recent quarter, Lite Strategy's actual EPS was -$2.76, missing the estimate of -$1.46 per share, resulting in a -88.56% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.